Allison Kutner

Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO).

Cooley advised Thirty Madison, a specialty healthcare company offering high-quality virtual specialized care for patients experiencing a range of conditions, on its definitive agreement to be acquired by Remedy Meds in an all-stock transaction valued in excess of $500 million.

Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on its definitive merger agreement to acquire scPharmaceuticals for up to $360 million

Cooley advised DigitalOcean Holdings (NYSE: DOCN), a simple, scalable cloud platform that democratizes cloud and artificial intelligence for digital native enterprises around the world, on its $625 million aggregate principal amount of convertible senior notes due 2030 in a private offering pursuant to Rule 144A under the Securities Act of 1933, including the exercise in full of the initial purchasers’ option to purchase up to an additional $75 million aggregate principal amount of the notes.

Cooley advised the underwriters of Heartflow, a leader in artificial intelligence technology for coronary artery disease, in connection with Heartflow’s $364.2 million upsized initial public offering.